CN3 Cost Effectiveness of Liposomal Doxorubicin Versus Paclitaxel for the Treatment of Aids-Ks
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1539
https://www.valueinhealthjournal.com/article/S1098-3015(11)03101-9/fulltext
Title :
CN3 Cost Effectiveness of Liposomal Doxorubicin Versus Paclitaxel for the Treatment of Aids-Ks
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)03101-9&doi=10.1016/j.jval.2011.08.1539
First page :
A539
Section Title :
Cancer Outcomes Research
Open access? :
No
Section Order :
1486